Search Results for Fibrosis

Commented Articles, Pathophysiology Articles

NAFLD and hepatic sexual dimorphism

This review by Philippe Lefebvre and Bart Staels (INSERM, CHU Lille, Institut Pasteur de Lille, France) discusses the accumulating evidence of sexual dimorphism in NAFLD. Liver pathophysiology is sexually dimorphic, and male individuals predominantly show more severe stages of non-alcoholic fatty liver, NASH and fibrosis than do female individuals...

Dr. G. Bozet, MD
October 12, 2021

NASH Observatory, Commented Articles, Pathophysiology Articles

Dynamic changes in liver macrophage subsets during NASH

Macrophage-mediated inflammation is critical in the pathogenesis of NASH. However, the underlying mechanisms remain unclear. In this study, S. Daemen et al. (Washington University School of Medicine, St. Louis, MI, USA) evaluated intra-hepatic macrophage composition in a mouse model of obesity with NAFLD and in a model of NASH...

Dr. G. Bozet, MD
September 8, 2021

NASH Observatory, Commented Articles, Definitions Articles, Epidemiology Articles

Prevalence of NAFLD and MAFLD in the US population

S. Ciardullo et G. Perseghin (Policlinico di Monza, and University of Milano Bicocca, Italy) performed a cross-sectional study of adults recruited in the 2017-2018 NHANES Survey, a representative sample of the general US population, in order to determine the prevalence of NAFLD, MAFLD and associated advanced fibrosis in the US population...

Dr. D. Beard
September 1, 2021

NASH Observatory, Commented Articles, Epidemiology Articles

Global epidemiology of NAFLD-related HCC

In this Review, D. Q. Huang et al. (National University Health System, Singapore) discuss the global epidemiology, projections, and risk factors for NAFLD-related HCC, and propose preventive strategies to tackle this growing problem. The prevalence of NAFLD-related HCC is high in several regions worldwide...

Dr. D. Beard
August 18, 2021

Management Articles, Commented Articles, NASH Observatory, Ppar Articles

Pharmacotherapy in NAFLD/NASH

This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD. Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates....

Dr. G. Bozet, MD
July 26, 2021

Management Articles, Commented Articles, Comorbidities Articles, NASH Observatory

European NAFLD guidelines: limitations when applied to T2D patients

G. Besutti et al. aimed to evaluate the feasibility and efficiency of a guidelines-compliant NAFLD assessment algorithm in patients with newly diagnosed type 2 diabetes. Consecutive patients newly diagnosed with T2D without coexisting liver disease or excessive alcohol consumption were enrolled. They were stratified...

Dr. G. Bozet, MD
July 14, 2021

NASH Observatory, Commented Articles, Comorbidities Articles, Diagnosis Articles

NAFLD in patients with schizophrenia: early detection should be conducted

ndividuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical...

Dr. D. Beard
July 14, 2021

NASH Observatory, Commented Articles, Pathophysiology Articles

From NAFLD/NASH to HCC: role of mitochondrial defects

This review by M. Longo et al. (IRCCS – Università degli Studi di Milano, Italy) discusses how mitochondrial defects may be translated into causative explanations of NAFLD-driven hepatocellular carcinoma. Acting as central metabolic hubs, the mitochondria rapidly adapt to different metabolic alterations...

Dr. G. Bozet, MD
July 5, 2021

NewsRoom

5th January, 2021. Inventiva announces design of Phase III clinical trial with lanifibranor in NASH Read more 15th June, 2020. Lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH).Read more…

Lila HNAT BENGUEDACH
June 30, 2021

NASH Observatory, Commented Articles, Diagnosis Articles

Assessment of imaging modalities against liver biopsy

Multiparametric MRI is a promising technique to assess hepatic steatosis, inflammation, and fibrosis, potentially enabling non-invasive identification of individuals with active and advanced stages of NAFLD. The aim of the current proof-of-principle study by M. A. Troelstra et al. (Amsterdam University Medical Centres, The ...

Dr. D. Beard
June 24, 2021

Diagnosis, Epidemiology

Imaging biomarkers in NAFLD: Could they avoid liver biopsy

There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm

Dr Romero Gomez
June 16, 2021

NASH Observatory, Commented Articles, Comorbidities Articles

Awareness of suffering of advanced liver disease in patients with T2D is remarkably low

The aim of the present population-based cross-sectional study is to estimate the awareness of liver disease among patients with T2D and whether it differs according to the degree of liver fibrosis estimated by transient elastography. The authors included all patients with T2D that participated in the 2017-2018 cycle of the NHAHES Survey and underwent...

Dr. D. Beard
June 16, 2021